drugset / Trial / NCT01911455
Study of Acamprosate in Fragile x Syndrome
Phase 1
Completed
46 enrolled
Children's Hospital Medical Center, Cincinnati
Rush University Medical Center · collab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
In this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with Fragile X Syndrome (FXS).
Timeline
- Start
- 2013-08-27
- Primary completion
- 2018-11-08
- Completion
- 2018-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acamprosate | Small molecule | 666 mg | — |
| Comparator | Acamprosate | Small molecule | 1332 mg | — |